Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Zacks Investment Research • Nov 21, 2025

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

AngioDynamics, Inc. ( ANGO ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Steven Lichtman - Oppenheimer & Co. Inc., Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good morning, everyone. Thank you for joining us.

Seeking Alpha • Nov 10, 2025

AngioDynamics to Participate in the UBS Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the UBS Global Healthcare Conference at 8:00 a.m. ET on Monday, Nov.

Business Wire • Oct 27, 2025

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and technologies that are transforming how people live, work, and receive care. For the past 25 years, TIME'.

Business Wire • Oct 13, 2025

ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves

AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.

Zacks Investment Research • Oct 3, 2025

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.

Benzinga • Oct 2, 2025

Why Did AngioDynamics Stock Pop Today?

AngioDynamics (ANGO 7.00%) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.

The Motley Fool • Oct 2, 2025

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.

Seeking Alpha • Oct 2, 2025

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 First Quarter Highlights   Quarter Ended August 31, 2025 Pro Forma* YoY Growth Net Sales $75.7 million.

Business Wire • Oct 2, 2025

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.

Zacks Investment Research • Oct 2, 2025